Daehan Nupharm Co.,Ltd. (KOSDAQ:054670)

Daehan Nupharm Statistics

Total Valuation

Daehan Nupharm has a market cap or net worth of KRW 100.35 billion. The enterprise value is 166.31 billion.

Market Cap	100.35B
Enterprise Value	166.31B

Important Dates

The last earnings date was Tuesday, December 2, 2025.

Earnings Date	Dec 2, 2025
Ex-Dividend Date	Dec 29, 2025

Share Statistics

Daehan Nupharm has 14.04 million shares outstanding.

Current Share Class	14.04M
Shares Outstanding	14.04M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	39.40%
Owned by Institutions (%)	0.32%
Float	8.22M

Valuation Ratios

The trailing PE ratio is 6.58.

PE Ratio	6.58
Forward PE	n/a
PS Ratio	0.50
PB Ratio	0.72
P/TBV Ratio	0.73
P/FCF Ratio	n/a
P/OCF Ratio	19.83
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.54, with an EV/FCF ratio of -3.68.

EV / Earnings	10.90
EV / Sales	0.82
EV / EBITDA	10.54
EV / EBIT	14.50
EV / FCF	-3.68

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.71.

Current Ratio	1.55
Quick Ratio	0.97
Debt / Equity	0.71
Debt / EBITDA	6.17
Debt / FCF	-2.19
Interest Coverage	7.02

Financial Efficiency

Return on equity (ROE) is 11.50% and return on invested capital (ROIC) is 5.88%.

Return on Equity (ROE)	11.50%
Return on Assets (ROA)	2.98%
Return on Invested Capital (ROIC)	5.88%
Return on Capital Employed (ROCE)	5.93%
Weighted Average Cost of Capital (WACC)	3.54%
Revenue Per Employee	887.73M
Profits Per Employee	66.92M
Employee Count	228
Asset Turnover	0.82
Inventory Turnover	2.84

Taxes

Income Tax	-274.54M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.26% in the last 52 weeks. The beta is 0.27, so Daehan Nupharm's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	+6.26%
50-Day Moving Average	6,950.00
200-Day Moving Average	6,929.25
Relative Strength Index (RSI)	54.94
Average Volume (20 Days)	112,291

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Daehan Nupharm had revenue of KRW 202.40 billion and earned 15.26 billion in profits.

Revenue	202.40B
Gross Profit	91.05B
Operating Income	11.72B
Pretax Income	14.98B
Net Income	15.26B
EBITDA	16.03B
EBIT	11.72B
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 33.00 billion in cash and 98.96 billion in debt, with a net cash position of -65.95 billion or -4,699.10 per share.

Cash & Cash Equivalents	33.00B
Total Debt	98.96B
Net Cash	-65.95B
Net Cash Per Share	-4,699.10
Equity (Book Value)	139.95B
Book Value Per Share	n/a
Working Capital	40.52B

Cash Flow

In the last 12 months, operating cash flow was 5.06 billion and capital expenditures -50.24 billion, giving a free cash flow of -45.18 billion.

Operating Cash Flow	5.06B
Capital Expenditures	-50.24B
Depreciation & Amortization	4.30B
Net Borrowing	38.77B
Free Cash Flow	-45.18B
FCF Per Share	-3,218.69

Margins

Gross margin is 44.99%, with operating and profit margins of 5.79% and 7.54%.

Gross Margin	44.99%
Operating Margin	5.79%
Pretax Margin	7.40%
Profit Margin	7.54%
EBITDA Margin	7.92%
EBIT Margin	5.79%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.37%.

Dividend Per Share	100.00
Dividend Yield	1.37%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	9.20%
Buyback Yield	n/a
Shareholder Yield	1.33%
Earnings Yield	15.20%
FCF Yield	-45.02%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Daehan Nupharm has an Altman Z-Score of 1.87 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.87
Piotroski F-Score	3